Equities Analysts Issue Forecasts for argenx Q3 Earnings

argenx SE (NASDAQ:ARGX) – Investment analysts at Wedbush increased their Q3 2025 earnings per share (EPS) estimates for argenx in a research note issued on Thursday, May 8th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of $5.38 per share for the quarter, up from their prior forecast of $5.17. Wedbush currently has a “Outperform” rating and a $715.00 target price on the stock. The consensus estimate for argenx’s current full-year earnings is $3.13 per share. Wedbush also issued estimates for argenx’s FY2025 earnings at $18.73 EPS and FY2027 earnings at $43.06 EPS.

A number of other equities research analysts also recently weighed in on ARGX. HC Wainwright restated a “buy” rating and set a $720.00 target price on shares of argenx in a research report on Tuesday, April 8th. Sanford C. Bernstein upgraded argenx from a “market perform” rating to an “outperform” rating in a report on Monday, March 17th. Robert W. Baird upgraded argenx from a “neutral” rating to an “outperform” rating and set a $680.00 price objective for the company in a report on Tuesday. Truist Financial reiterated a “buy” rating and issued a $700.00 price objective (up previously from $660.00) on shares of argenx in a report on Tuesday, January 14th. Finally, Oppenheimer upped their price objective on argenx from $704.00 to $708.00 and gave the company an “outperform” rating in a report on Friday, May 9th. Two analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $697.94.

argenx Stock Down 3.3%

ARGX stock opened at $542.47 on Monday. The company has a market cap of $33.12 billion, a P/E ratio of -616.44 and a beta of 0.57. argenx has a twelve month low of $352.77 and a twelve month high of $678.21. The business has a fifty day moving average of $593.35 and a 200-day moving average of $613.35.

argenx (NASDAQ:ARGX) last released its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.32 by $0.26. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $748.34 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%.

Institutional Investors Weigh In On argenx

Several large investors have recently modified their holdings of the business. GeoWealth Management LLC boosted its position in shares of argenx by 56.3% during the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock worth $31,000 after buying an additional 18 shares during the period. Whipplewood Advisors LLC acquired a new position in shares of argenx during the fourth quarter worth about $37,000. Global Retirement Partners LLC boosted its position in shares of argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after buying an additional 48 shares during the period. FIL Ltd acquired a new position in shares of argenx during the fourth quarter worth about $38,000. Finally, Rakuten Securities Inc. boosted its position in shares of argenx by 56.4% during the first quarter. Rakuten Securities Inc. now owns 61 shares of the company’s stock worth $36,000 after buying an additional 22 shares during the period. 60.32% of the stock is currently owned by institutional investors.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.